Stock 9688 ZAI LAB LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Zai Lab Limited Stock Hong Kong S.E.

Equities

9688

KYG9887T1168

Pharmaceuticals

Delayed Hong Kong S.E.
Other stock markets
 10:46:35 2024-05-19 pm EDT 		5-day change 1st Jan Change
15.3 HKD -1.29% Intraday chart for Zai Lab Limited -9.05% -28.93%
May. 16 Asian Equities Traded in the US as American Depositary Receipts Ease in Thursday Trading MT
May. 14 Zai Lab's Supplemental Application for Autoimmune Disease Treatment Accepted by China Regulator MT
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 389M 3.04B Sales 2025 * 617M 4.82B Capitalization 1.92B 15.02B
Net income 2024 * -277M -2.16B Net income 2025 * -130M -1.01B EV / Sales 2024 * 3.56 x
Net cash position 2024 * 538M 4.2B Net cash position 2025 * 275M 2.15B EV / Sales 2025 * 2.67 x
P/E ratio 2024 *
-7.06 x
P/E ratio 2025 *
-18.2 x
Employees 2,175
Yield 2024 *
-
Yield 2025 *
1.03%
Free-Float 9.91%
More Fundamentals * Assessed data

Chart Zai Lab Limited

Dynamic Chart

Latest news about Zai Lab Limited

Asian Equities Traded in the US as American Depositary Receipts Ease in Thursday Trading MT
Zai Lab's Supplemental Application for Autoimmune Disease Treatment Accepted by China Regulator MT
Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy in China CI
Asian Equities Traded in the US as American Depositary Receipts Begin Week Higher MT
Zai Lab Says China Approves New Drug Application for Lung Cancer Treatment Augtyro MT
Zai Lab's Cancer Drug Gets NDA Approval in China MT
Zai Lab's Shares Rise After Q1 Beat MT
Asian Equities Traded in the US as American Depositary Receipts Trend Lower Thursday MT
Top Premarket Gainers MT
Transcript : Zai Lab Limited, Q1 2024 Earnings Call, May 09, 2024
Zai Lab Q1 Loss Widens Despite Higher Revenue MT
Tech Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Slightly Higher in Monday Trading MT
Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Friday Trading, End Week Over 2% Higher MT
Asian Equities Traded in the US as American Depositary Receipts Remain Flat in Wednesday Trading MT
Zai Lab CEO, Others 'Do Not Anticipate' Selling Company Shares in Remainder of 2024 MT
More news

Latest transcript on Zai Lab Limited

Logo Zai Lab Limited
Zai Lab Limited, Q1 2024 Earnings Call, May 09, 2024
More transcripts

Analyst Recommendations on Zai Lab Limited

Zai Lab CEO, Others 'Do Not Anticipate' Selling Company Shares in Remainder of 2024 MT
Zai Lab Grants Share Options, Restricted Share Units to Eligible Personnel MT
Morgan Stanley Starts Coverage on Zai Lab with Overweight Rating, $47.50 Price Target MT
Citigroup Adjusts Price Target on Zai Lab to $128 From $130, Maintains Buy Rating MT
Goldman Sachs Lowers Price Target on Zai Lab to $73.34 From $82.47, Maintains Buy Rating MT
More recommendations

Press releases Zai Lab Limited

Zai Lab Announces Participation in May and June Investor Conferences BU
Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China BU
Zai Lab Announces Approval of AUGTYRO for Patients with ROS1-positive NSCLC by China's NMPA AQ
Zai Lab Announces Approval of AUGTYRO™ (repotrectinib) for Patients with ROS1-positive NSCLC by China’s NMPA BU
Zai Lab : Corporate Presentation PU
More press releases

News in other languages on Zai Lab Limited

Hong Kong se convierte en el principal mercado para las cotizaciones chinas, según HKEX -- Market Talk
Tweede kwartaal Argen-x in teken lancering Vyvgart
Brussel fors hoger van start na Fed-rally op Wall Street
Argenx boekt eerste omzet met Vyvgart
EN DIRECTO DESDE LOS MERCADOS: Stellantis, Wendel, Soitec, Umanis, Tod's, Deutsche Telekom, Oracle, Rivian...
More news

Quotes and Performance

1 day-2.45%
1 week-10.00%
Current month+16.31%
1 month+32.17%
3 months-3.82%
6 months-31.43%
Current year-29.67%
More quotes

Highs and lows

1 week
15.00
Extreme 15
17.26
1 month
10.88
Extreme 10.88
17.98
Current year
10.56
Extreme 10.56
21.65
1 year
10.56
Extreme 10.56
28.25
3 years
10.56
Extreme 10.56
142.00
5 years
10.56
Extreme 10.56
151.20
10 years
10.56
Extreme 10.56
151.20
More quotes

Managers and Directors - Zai Lab Limited

Managers TitleAgeSince
Ying Du CEO
 Chief Executive Officer 59 14-03-31
Ya jing Chen DFI
 Director of Finance/CFO 56 21-08-31
Joshua Smiley PSD
 President 54 22-07-31
Members of the board TitleAgeSince
John D. Diekman BRD
 Director/Board Member 81 16-12-31
Peter Wirth BRD
 Director/Board Member 73 16-12-31
Lonnie Moulder BRD
 Director/Board Member 66 18-12-31
More insiders

ETFs positioned on Zai Lab Limited

Name Weight AuM 1st Jan change Investor Rating
KRANESHARES MSCI CHINA ESG LEADERS ETF - USD ETF KraneShares MSCI China ESG Leaders ETF - USD
0.31% 4 M€ -11.56%
KRANESHARES EMERGING MARKET HEALTHCARE INDEX ETF - DISTRIBUTING - USD ETF KraneShares Emerging Market Healthcare Index ETF - Distributing - USD
0.28% 2 M€ -14.14%
AMUNDI INDEX MSCI EMERGING MARKETS UCITS ETF DR (C) - EUR ETF AMUNDI INDEX MSCI EMERGING MARKETS UCITS ETF DR (C) - EUR
0.04% 2,867 M€ +11.35% -
More ETFs positioned on Zai Lab Limited

Quotes

Date Price Change Volume
24-05-19 15.3 -1.29% 1 877 600
24-05-17 15.5 -3.85% 5,841,580
24-05-16 16.12 -3.59% 12,616,910
24-05-14 16.72 -0.48% 4,997,071
24-05-13 16.8 +3.70% 11,888,200

Delayed Quote Hong Kong S.E., May 19, 2024 at 09:42 pm EDT

More quotes

Company Profile

Zai Lab Ltd is a holding company mainly engaged in the biopharmaceutical field. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including oncology, autoimmune and infectious diseases fields. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include Niraparib (ZL-2306), ZL-2103, ZL-1101 and others.
Sector
Pharmaceuticals
Calendar
2024-05-22 - J.P. Morgan Global China Summit
More about the company

Income Statement Evolution

More financial data

Ratings for Zai Lab Limited

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
19.4 USD
Average target price
51.37 USD
Spread / Average Target
+164.81%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
CSL LIMITED Stock CSL Limited
-2.59% 90.45B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+3.68% 41.45B
BIOGEN INC. Stock Biogen Inc.
-10.90% 33.57B
UCB Stock UCB
+58.05% 25.73B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-19.56% 14.73B
INCYTE CORPORATION Stock Incyte Corporation
-9.06% 12.82B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-11.34% 11.7B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-43.53% 11.44B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+3.75% 8.79B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. ZLAB Stock
  4. 9688 Stock
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW